Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Dyne Therapeutics Inc

Healthcare US DYN

18.375USD
0.39(2.14%)

Last update at 2026-06-04T17:49:00Z

Day Range

18.1518.74
LowHigh

52 Week Range

6.3647.45
LowHigh

Fundamentals

  • Previous Close 17.99
  • Market Cap1344.68M
  • Volume585819
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-395.31200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -168.09900M -149.29100M -59.43700M -14.85900M -4.81100M
Minority interest - - - - -
Net income -165.23700M -149.28300M -58.73700M -13.53600M -4.81100M
Selling general administrative 28.20M 28.72M 13.45M 2.79M 0.52M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 1.68M 1.09M 0.70M 0.27M 0.02M
Ebit -172.64500M -150.02500M -59.34700M -13.82600M -4.81100M
Ebitda -170.96200M -148.20300M -58.64700M -14.58800M -4.78700M
Depreciation and amortization 1.68M 1.82M 0.70M -0.76200M 0.02M
Non operating income net other - - - - -
Operating income -170.96200M -150.02500M -58.64700M -13.82600M -4.79500M
Other operating expenses 170.96M 150.03M 58.65M 13.83M 4.79M
Interest expense 2.92M 0.74M 0.40M 0.29M 0.00500M
Tax provision - - - - -
Interest income 2.92M 0.74M 0.06M 0.29M 0.00500M
Net interest income 2.92M 0.74M -0.34000M 0.29M 0.00500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.86200M -0.00800M -0.70000M -1.32300M -0.01100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 170.96M 150.03M 58.65M 13.83M 4.79M
Cost of revenue - - - - -
Total other income expense net 2.86M 0.73M -0.79000M -1.03300M -0.02100M
Discontinued operations - - - - -
Net income from continuing ops -168.09800M -149.29100M -59.43700M -14.85900M -4.81100M
Net income applicable to common shares -168.09900M -149.29100M -59.43700M -14.85900M -4.81100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 691.23M 165.08M 306.32M 425.66M 353.33M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 17.01M 6.28M 9.58M 5.82M 3.77M
Total liab 61.40M 73.79M 53.96M 57.47M 10.97M
Total stockholder equity 629.84M 91.29M 252.36M 368.20M 342.37M
Deferred long term liab - - - - -
Other current liab 30.85M 23.44M 18.22M 20.80M 7.53M
Common stock 0.01000M 0.00600M 0.00600M 0.00600M 0.00500M
Capital stock 0.01000M 0.00600M 0.00600M 0.00600M 0.00500M
Retained earnings -949.92800M -632.51000M -396.57300M -228.47400M -79.18300M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 2.32M 2.31M 2.30M
Cash 435.45M 121.63M 172.15M 200.82M 300.85M
Cash and equivalents - - - - -
Total current liabilities 42.26M 51.09M 28.09M 28.72M 10.97M
Current deferred revenue - - - - -
Net debt -411.46100M -94.21100M -141.66400M -168.18900M -300.85200M
Short term debt 4.85M 4.72M 4.61M 3.89M -
Short long term debt - - - - -
Short long term debt total 23.99M 27.41M 30.48M 32.64M -
Other stockholder equity 1579.75M 723.80M 649.50M 596.93M 421.57M
Property plant equipment - - 38.41M 40.96M 1.95M
Total current assets 659.28M 129.38M 256.01M 382.39M 345.31M
Long term investments - - - - -
Net tangible assets - - 252.36M 368.20M 342.37M
Short term investments 206.82M 1.47M 83.86M 175.75M 44.46M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 6.56M 22.94M 5.26M 4.03M 3.44M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00600M - -0.57100M -0.26900M -0.02700M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.94M -0.00000M 11.90M 2.31M 6.07M
Deferred long term asset charges - - - - -
Non current assets total 31.95M 35.71M 50.31M 43.27M 8.02M
Capital lease obligations 23.99M 27.41M 30.48M 32.64M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 87.20M -134.27400M -45.66100M -1.64700M -0.13400M
Change to liabilities -1.23500M 13.70M 8.57M 1.69M 0.64M
Total cashflows from investing activities 87.20M -137.89200M -45.66100M -1.64700M -0.13400M
Net borrowings - - -0.06400M -0.06400M -0.06400M
Total cash from financing activities 37.39M 157.82M 380.69M 19.99M 12.42M
Change to operating activities -4.14400M -4.44600M -3.45500M -0.28400M -0.03400M
Net income -168.09900M -149.29100M -59.43700M -14.85900M -4.81100M
Change in cash -29.05300M -99.63400M 288.52M 6.51M 12.42M
Begin period cash flow 203.52M 303.15M 14.63M 8.12M -4.29800M
End period cash flow 174.47M 203.52M 303.15M 14.63M 8.12M
Total cash from operating activities -153.64500M -119.56300M -46.50800M -11.83400M -4.16400M
Issuance of capital stock 36.86M 157.24M 381.17M 19.99M 7.42M
Depreciation 1.68M 1.09M 0.70M 0.27M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 19.99M 7.42M
Other cashflows from financing activities 0.53M 0.58M 144.30M -1.64700M 12.41M
Change to netincome 18.15M 19.38M 7.05M 1.35M 0.02M
Capital expenditures 3.07M 3.62M 1.16M 1.65M 0.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -5.37900M 9.26M 5.11M 1.41M 0.60M
Stock based compensation 15.18M 17.54M 6.59M 0.03M 0.00100M
Other non cash items 2.97M -0.74600M 0.51M 1.32M 0.02M
Free cash flow -156.71200M -123.18100M -47.66900M -13.48100M -4.29800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
DYN
Dyne Therapeutics Inc		 0.39 2.14% 18.38 - - - 2.01 -8.8653
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics Inc

1560 Trapelo Road, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Joshua T. Brumm CEO, Pres & Director 1978
Ms. Susanna Gatti High M.B.A. Chief Operating Officer 1968
Dr. Oxana Beskrovnaya Ph.D. Chief Scientific Officer 1961
Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor 1965
Mr. Gene Kim VP of Fin. 1977
Mr. Richard William Scalzo M.B.A. Sr. VP, Head of Fin. & Admin. and Treasurer 1986
Ms. Amy Reilly Sr. VP and Head of Corp. Communications & Investor Relations 1974
Ms. Kate Mitchell VP & Head of HR NA
Dr. Thomas-Christian Mix M.D., M.S. Sr. VP of Pharmacovigilance 1967
Ms. Debra Feldman Sr. VP & Head of Regulatory Affairs 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.